Attempts at improving therapeutic ratio have addressed radiobiological theories in vogue. The use of radiosensitisers (MRC Working Party, 1983) hyperbaric oxygen (Chang, 1977) and neutron beam therapy (Catterall et al.. 1980 , Duncan et al., 1986 Laramore et al., 1988) to overcome the presumed problem of hypoxia have met with little success. The technical difficulties in the application of hyperbaric oxygen and neutrons have meant that most of the studies have included small numbers of patients and could be criticised because of their low discriminating power. However, they have not shown a significant survival advantage and the likely magnitude of a potential difference would not justify such inaccessible technology.
Radiobiological theory more recently turned to cell kinetic differences between brain tumour and normal brain tissue. The high proliferation rate of high grade gliomas (Hoshino et al., 1980 (Hoshino et al., . 1985 suggested that accelerated fractionation, which shortens the overall treatment time, may further inhibit the regeneration of tumour cells. By giving more than one fraction per day tumour repopulation during treatment is reduced with a potential for a better tumour control for a given dose level, providing there is no increase in late normal tissue injury (Thames et al., 1983) . The kinetics of repair of rat spinal cord, which is used as the model of late injury of the central nervous system, is relatively slow (Ang et al., 1984 Early studies have not demonstrated a survival advantage for accelerated radiotherapy (Douglas et al., 1982; Payne et al., 1982; Keim et al., 1987) . Nevertheless, treatment can be completed in 2-4 weeks with little adverse effect and this avoids protracted 6-week therapy, which is often unacceptable in patients with limited prognosis. The low toxicity demonstrated in these studies cannot be considered as proof of safety of accelerated fractionation as the survival of the patients studied is often too short for the full expression of late CNS injury.
Hyperfractionation, the use of small dose fractions in the same overall treatment time, exploits the differences in repair capacity between tumour and late responding normal tissues. In CNS radiotherapy it may allow for a higher total dose and result in increased tumour cell kill. Small randomised studies of hyperfractionation have yielded conflicting results (Fulton et al., 1984; Green et al., 1984; Packer et al., 1987; Ludgate et al., 1988) . Overall there is little survival advantage, although an optimum dose level may not have been reached. Increasing the total dose using small doses per fraction is being tested further (Freeman et al., 1988 ) but this will have to be done with caution as the actual sparing of late tissue damage with gradual reduction of dose per fraction from 2 to 1 Gy is less than would be predicted from radiobiological models (van der Schueren et al., 1988) .
Halogenated pyrimidine analogues BUDR and IUDR are taken up in the DNA of cycling cells and act as selective radiosensitisers for proliferating tissues (Kinsella et al., 1987) . They have been administered throughout the course of radiotherapy in glioma patients (Kinsella et al., 1988; Greenberg et al., 1988 ) but a survival benefit with this approach is yet to be demonstrated. This will require large randomised studies as the experimental enhancement ratio is relatively small and the tumour cell uptake of these agents may not be adequate.
Inclreasing radiation dose
The major advance in neuro-oncology has come from stereotactic neurosurgical technology. More accurate tumour definition with three-dimensional image reconstruction allows for precise biopsy and tumour excision with computer-aided systems (Kelly, 1987) . The techniques have also been adapted to improve tumour localisation and for more accurate delivery of interstitial or external beam radiotherapy. On theoretical grounds it should be possible to increase tumour dose with no influence on normal tissue damage by reducing the volume of normal brain irradiated (Lyman, 1985) . This is a reasonable approach and it may improve results, but only if high grade gliomas are truly localised tumours and if higher radiation dose would result in better tumour control.
The localised nature of glial tumours is a contentious issue, discussed fully in a recent review (Halperin et al., 1988) . The debate centres around the correlation between the apparent tumour margin seen on CT scan (or other imaging procedure) and the histological evidence of tumour spread. Hochberg & Pruitt (1980) reported that 81% of tumours recur within 2cm of the tumour margin. With current histological techniques and three-dimensional reconstruction the tumour invasion beyond the CT margin is more variable and exceeds 3cm in up to 13% of cases (Burger et al., 1988) . Nevertheless, tumour recurs locally in the majority of patients (Hochberg et al., 1980) and the main cause of death is the progression of disease at the primary site with only 5-9% developing multiple lesions (Choucair et al., 1986; Barnard et al., 1987) . More accurate tumour localisation and more effective local treatment may, therefore, cure a proportion of patients with truly circumscribed disease. If the current techniques for detection of tumour cells underestimate tumour spread, better local treatment may prolong diseasefree survival with little effect on long-term survival as recurrences may occur further from the putative tumour margin.
The grounds for optimism that increasing radiation dose may achieve better tumour control are based on randomised studies of the BTSG (Walker et al., 1979 ). An improvement in median survival was demonstrated with dose increased from 50 to 60 Gy, although there was no increase in the number of long-term survivors with the higher dose of radiation. It is not clear if even higher doses would provide additional benefit. Early phase II studies of small numbers of selected patients treated to doses up to 80 Gy suggested a prolongation of survival (Salazar et al., 1979 ) but a randomised RTOG study (Chang et al., 1983) failed to show an improvement with a boost to a total tumour dose of 70 Gy compared to 60 Gy. Optimal therapeutic ratio with large volume irradiation and conventional fractionation is, probably, reached at 55-60 Gy. Pushing the dose to large target volumes beyond the conventional radiation tolerance is unlikely to lead to improved results. This, however, may not hold for irradiation of small target volumes.
The neuro-oncology world has been swept by a wave of enthusiasm for interstitial radiotherapy which delivers high doses of radiation to small tumour volume. The doses of radiation used are well beyond known radiation tolerance and this is a departure from standard radiotherapy practice in the CNS. The aim is to induce cell kill without preservation of residual normal brain tissue at the tumour site, as it is assumed that there is no important functional nervous tissue within the confines of tumour as seen on CT scan. With high radiation doses there is likely to be some normal tissue damage, particularly at the periphery of the tumour, and this may limit such technique to small volumes and to tumours within less functionally important regions of the brain.
There are many publications describing interstitial radiotherapy techniques using either iodine-125 or iridium-192 sources (e.g. Gutin et al., 1984; Findlay et al., 1985; Eddy et al., 1986; Salcman et al., 1986; Ostertag, 1987; Mundinger, 1987) (Moser, 1988) . Nevertheless, the reported interstitial radiotherapy experience is as yet the best that has been achieved and should be tested in controlled prospective studies.
Brachytherapy is an invasive technique within a province of a highly specialised neurosurgical centre. A similar dose distribution may be achieved with stereotactic external beam radiotherapy. Small volume focal radiation was initially delivered with a dedicated 'gamma unit' containing over 200 focused cobalt-60 sources (for review see Leksell, 1987) . More recently a number of centres have developed stereotactic external beam radiotherapy with multiple noncoplanar arcs of rotation or simultaneous gantry and couch movement ('dynamic radiotherapy') using a standard linear accelerator (Colombo et al., 1985; Hartmann et al., 1985; Houdek et al., 1985; Greitz et al., 1986; Podgorsak et al., 1988; Lutz et al., 1988) . Single high-dose stereotactic irradiation (described as 'radiosurgery') has been used for the treatment of arterio-venous malformations, but the technique is also suitable for radiotherapy of brain tumours. With the development of relocatable fixation devices (Gill et al., 1989) it will be possible to deliver fractionated focal irradiation on equipment available in most radiotherapy centres. Technical progress is not necessarily clinical progress and any benefit will have to be proven in well designed prospective studies.
Any attempt at improving results with more aggressive therapy must look not only at survival but also at quality of life. Patients with brain tumours suffer from multiple functional disorders affecting mobility, communication, cognitive function and personality. Quality of life measurements such as Karnofsky scale are not adequate for assessing brain tumour patients and any future studies in the treatment of CNS tumours should therefore include full evaluation of the patient's functional status. Gloom about the current outcome of treatment of high grade gliomas may be justified but often leads to despondency which is unlikely to benefit either present or future patients with brain tumours. While we continue looking for new ways of controlling the aggressive proliferation of malignant glial tissue there is scope for sharpening the existing tools. Radiotherapy is an effective treatment modality and both new and existing technology can be developed further with a potential for improved results. However, any survival advantage which may be gained from new treatment must be accompanied by improved quality of life or the efforts will have been wasted. 
